Navigation Links
Genmab Announces Upcoming Ofatumumab Studies
Date:8/25/2008

Front Line CLL, NHL and CLL Retreatment and Japanese Development Studies

Planned

COPENHAGEN, Denmark, August 25 /PRNewswire-FirstCall/ -- Genmab has announced plans to begin four studies of ofatumumab in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

Genmab A/S (OMX: GEN) announced today plans to begin four studies of ofatumumab in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL) this year.

"Genmab and GSK have worked diligently to expand the ofatumumab development program to maximize the value of the antibody for patients and shareholders since our collaboration began," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab."The new studies we are initiating this year will examine the potential of ofatumumab in Japan as well as a number of new treatment settings - retreatment, maintenance and front line with chlorambucil."

Phase III CLL front line chlorambucil combination This open-label, parallel-arm study will include 444 patients with previously untreated CLL.Patients in the study will be randomized to receive ofatumumab in combination with chlorambucil or chlorambucil alone.Patients receiving ofatumumab in combination with chlorambucil will receive one infusion of ofatumumab at 300 mg, one infusion at 1000 mg a week later, followed by up to 11 monthly infusions at 1000 mg.Patients will be evaluated for disease status one month following last treatment then every 3 months for 5 years.

The primary objective of the study is to evaluate the progression free survival of ofatumumab in combination with chlorambucil therapy versus chlorambucil therapy alone for the treatment of front line CLL.

Phase II CLL ofatumumab retreatment and maintenance treatment study This study will examine the retreatment and maintenance treatment of refractory CLL patients who participated in the ongoing Phase III CLL study and had disease progression following
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DAHANCA Initiates Head and Neck Cancer Study With Genmabs HuMax-EGFr
2. Bionomics Achieves US$1 Million Milestone Payment from Genmab
3. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
4. Genmab Announces Updates on Phase III Cancer Studies
5. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
6. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
7. Genmab Reaches Milestone in Ofatumumab Collaboration
8. Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
9. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014  The National Association of Drug ... achieved by the real-time, pseudoephedrine (PSE) blocking system ... Log Exchange (NPLEx), automatically blocks unlawful PSE sales ... offenders and make arrests. Data released by NPLEx ... blocked the sale of more than 32,105 ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down methamphetamine offenders and make arrests. Data released ... Missouri blocked the sale of more ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com ... report is available in its catalogue: ... Infection Control (Sterilization, Disinfection, Testing and ... Given the cost ... demand has increased for solutions that ...
Breaking Medicine Technology:Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6
... Cetrorelix showed good safety and tolerability profile ... level,Japanese partner Shionogi initiates Phase 2b trial, ... AEterna,Zentaris Inc. along with its Japanese partner ... for a Phase 2a trial with,cetrorelix in ...
... WIRE)--Mar 22, 2007 - Nutra Pharma,Corp. (OTCBB: ... for HIV and Multiple Sclerosis has today ... received notification of,acceptance of its paper for ... conference issue., The article, entitled "Alpha-Cobratoxin as ...
Cached Medicine Technology:AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 2AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 3AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 4Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 2Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 3
(Date:8/21/2014)... August 21, 2014 Hunhu Healthcare, ... solutions, announced today that it has entered into a ... practices, mobile technology and predictive analytics for recruiting, leveraging ... , According to Michael Emerson , co-founder and ... two patents on the technology used in what he ...
(Date:8/21/2014)... DMG Productions announces the upcoming airing of ... Monday, August 25, 2014 at 7:00 a.m. EST and ... this episode, Innovations will go behind-the-scenes to demonstrate how ... performance. Audiences will be amazed by the park's that ... and providing access to real musical instruments. , Audiences ...
(Date:8/21/2014)... Poorly-made dental restorations – whether produced in America ... health consequences for patients. To ensure better outcomes for ... and patients have a full understanding of where their ... used in the process. , Some patients believe their ... not even think twice about where their restorations are ...
(Date:8/21/2014)... Studies find that participating in a juice ... clearer skin, more energy, refresh the taste buds, help lose ... wellness center in Beverly Hills, is excited to offer guests ... their recovery room. , β€œIt’s important that we offer patients ... surgery in our Los Angeles recovery room ,” says ...
(Date:8/21/2014)... HIPAA Secure Now! rolled out its EHR (electronic ... vendors to now offer their customers a HIPAA security ... , HIPAA Secure Now! provides risk analysis services, ... U.S. The company assesses the risks of storing and ... and device used by the practice. , HIPAA ...
Breaking Medicine News(10 mins):Health News:Hunhu Healthcare Enters into Licensing Agreement with Mayo Clinic 2Health News:Announcing New Episode Airing of Innovations on Monday August 25, 2014 via Discovery Channel 2Health News:4 Questions to Ask Before Your Next Dentist Appointment 2Health News:4 Questions to Ask Before Your Next Dentist Appointment 3Health News:Los Angeles Surgery Recovery Center Now Offering Juice Cleanses 2Health News:Los Angeles Surgery Recovery Center Now Offering Juice Cleanses 3Health News:HIPAA Secure Now! Ramps up EHR Partner Program, Helps Healthcare Providers Achieve Meaningful Use under Revised CMS Deadlines 2
... April 27 minor surgery reveals inoperable pancreatic and spinal ... Hennie Page had finally settled into a quiet life ... enjoys looking at his,paintings and frequent visits from his ... the world in years past -- leading,chartered cruises in ...
... 3 Market competition is,mounting to win the ... investigators. Field research shows that the most sought-after,clinical ... trial,invitations that they receive at their labs and ... to manage the art,and science of investigator recruitment., ...
... Grills, Photo Books and Shaving Kits Are Just a ... CVS/pharmacy,s 6,300 Convenient U.S. Locations, WOONSOCKET, R.I., June ... locations nationwide, offers,shoppers a wide selection of affordable, department ... just the right gift., "Consumers are scaling back ...
... . , Images of the inside of the intestine can ... no larger than a candy. It makes its way through the ... receiver which the patient carries on a belt. This device stores ... identify any hemorrhages or cysts. However, the camera is not very ...
... Flashpoint Medica, a full-service,healthcare advertising agency and member ... launched Flashlight Interactive, a new business unit devoted ... by agency veteran Kristen,Goelz, who joins the company ... Interactive will offer a variety of programs and,capabilities, ...
... study at the Montreal Neurological Institute at McGill University ... motor nerve cells (motor neurons) - cells that control ... a range of conditions involving nerve cell loss or ... as ALS, also known as Lou Gehrig,s disease. , ...
Cached Medicine News:Health News:Sherwood, Oregon Sailor, 78, Goes on Final Voyage 2Health News:Best Practice Toolkit Supports Recruitment of Top Clinical Investigators 2Health News:Practical Gear and Personal Gadgets: CVS/pharmacy Offers a Wide Selection of Affordable Gifts to Delight Dad This Father's Day 2Health News:Practical Gear and Personal Gadgets: CVS/pharmacy Offers a Wide Selection of Affordable Gifts to Delight Dad This Father's Day 3Health News:Magnet-controlled camera in the body 2Health News:Flashpoint Launches Flashlight Interactive, Names Kristen Goelz Head of New Division 2Health News:Finding clues for nerve cell repair 2
Inquire...
... design makes positioning quick and ... wheelchair accessible and can support ... lbs. The AIT-8B provides stable ... units and includes a motorized ...
If youre looking to expand your projection capabilities, without a major capital investment, consider Topcons CP-5D Chart Projector....
... FDA-Approved BV-1000 is the worlds ... system. With the BV-1000, Topcon ... of refracting instruments. This innovative ... binocular auto-refractor, auto-keratometer, automatic chart ...
Medicine Products: